SavedAdd your journal

Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2017 / Cilt: 25 - Sayı: 4

The Levitronix CentriMag ventricular assist device as a bridge to decision in patients with end-stage heart failure: Our single-center experience

Son dönem kalp yetmezliği olan hastalarda karara köprülemede Levitronix CentriMag ventriküler destek cihazı: Tek merkez deneyimimiz

Mehmet BALKANAY
Murat Bülent RABUŞ
Salih SALİHİ
Ali FEDAKAR
Sarkhan HASANOV
Deniz ÇEVİRME
Pages
543–549
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Non- survivors had a higher rate of sepsis and renal failure, compared to the survivors (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: In this study, we report early outcomes of Levitronix CentriMag device implantation for bridge to decision for patients with end-stage heart failure in a single center.Methods: We retrospectively analyzed data of a total of 41 patients(30 males, 11 females: mean age 30.2±15 years; range 7 to 59 years) with end-stage heart failure who received a Levitronix CentriMag support for bridge to decision between December 2010 and September 2014.
📊
Key Findings & Data:Devices were implanted in the left (n=38), right (n=1), or biventricular (n=2) configuration.
💡
Conclusion & Impact:Non- survivors had a higher rate of sepsis and renal failure, compared to the survivors (p
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: In this study, we report early outcomes of Levitronix CentriMag device implantation for bridge to decision for patients with end-stage heart failure in a single center.Methods: We retrospectively analyzed data of a total of 41 patients(30 males, 11 females: mean age 30.2±15 years; range 7 to 59 years) with end-stage heart failure who received a Levitronix CentriMag support for bridge to decision between December 2010 and September 2014. Devices were implanted in the left (n=38), right (n=1), or biventricular (n=2) configuration. Support was continued until recovery, transplantation or implantation of a long-term ventricular assist device.Results: The mean preoperative left ventricular ejection fraction was 17±2.3%. The mean support time was 38 (range 1 to 192) days. Sixteen patients (39%) survived and moved on to the next phase of the treatment. Of these patients, 11 (27%) underwent cardiac transplantation operations and five (12%) received long-term ventricular assist devices. After the CentriMag implantation, 30-day survival rate was 49% in 20 patients. Bleeding requiring re-operation was observed in 13 patients (32%). Two patients (4.8%) had sternal wound infections. Device dysfunction was observed in one patient (2.4%). Non- survivors had a higher rate of sepsis and renal failure, compared to the survivors (p

Özet

Amaç: Bu çalışmada tek bir merkezde son dönem kalp yetmezliği olan hastalarda karara köprülemede Levitronix CentriMag ventriküler destek cihazı implantasyonunun erken dönem sonuçları sunuldu. Çalış­ma­ planı:­ Aralık 2010 - Eylül 2014 tarihleri arasında, karara köprüleme amacıyla Levitronix CentriMag desteği uygulanmış olan toplam 41 son dönem kalp yetmezliği hastasının (30 erkek, 11 kadın; ort. yaş 30.2±15 yıl; dağılım 7-59 yıl) verileri retrospektif olarak incelendi. Cihazlar sol (n=38), sağ (n=1) veya biventriküler (n=2) konfigürasyonda yerleştirildi. Destek iyileşmeye, transplantasyona veya uzun dönem ventriküler destek cihazı takılana kadar sürdürüldü. Bulgu­lar:­ Hastaların ameliyat öncesi ortalama sol ventrikül ejeksiyon fraksiyonları %17±2.3 idi. Ortalama destek süresi 38 (dağılım 1-192) gündü. On altı hasta (%39) yaşamını sürdürdü ve tedavinin bir sonraki aşamasına geçti. Bu hastalardan 11’ine (%27) kalp nakli yapıldı ve beş hastaya (%12) uzun dönem ventriküler destek cihazı yerleştirildi. CentriMag yerleştirildikten sonra 30 günlük sağkalım oranı 20 hastada %49 idi. On üç hastada (%32) yeniden ameliyat gerektiren kanama gözlendi. İki hastada (%4.8) sternal yara enfeksiyonları vardı. Bir hastada (%2.4) cihaz disfonksiyonu gözlendi. Sağkalan hastalara kıyasla, kaybedilen hastalarda daha yüksek oranda sepsis ve renal yetmezlik vardı (p

🔖

Cite This Article

BALKANAY, M., RABUŞ, M. B., SALİHİ, S., FEDAKAR, A., HASANOV, S., ÇEVİRME, D. (2022). The Levitronix CentriMag ventricular assist device as a bridge to decision in patients with end-stage heart failure: Our single-center experience. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 25 - Sayı: 4, 543–549. https://ajindex.com/articles/624706

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Yılmaz MB, Akar AR, Ekmekçi A, Nalbantgil S, Sade LE, Eren M, et al. Advanced heart failure and future of mechanical assist devices: a Consensus Report on Cardiology and Cardiovascular Surgery. Turk Gogus Kalp Dama 2016;24:201-12. 25. Borisenko O, Wylie G, Payne J, Bjessmo S, Smith J, Yonan N, et al. Thoratec CentriMag for temporary treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency: a systematic literature review and meta-analysis of observational studies. ASAIO J 2014;60:487-97. 24. John R, Long JW, Massey HT, Griffith BP, Sun BC, Tector AJ, et al. Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory support. J Thorac Cardiovasc Surg 2011;141:932-9. 23. Worku B, Naka Y, Pak SW, Cheema FH, Siddiqui OT, Jain J, et al. Predictors of mortality after short-term ventricular assist device placement. Ann Thorac Surg 2011;92:1608-12. 22. Zeriouh M, Mohite P, Raj B, Sabashnikov A, Fatullayev J, Saez DG, et al. Short-term ventricular assist device as a bridge to decision in cardiogenic shock: is it a justified strategy? Int J Artif Organs 2016;39:0. 21. Takayama H, Soni L, Kalesan B, Truby LK, Ota T, Cedola S, et al. Bridge-to- decision therapy with a continuous-flow external ventricular assist device in refractory cardiogenic shock of various causes. Circ Heart Fail 2014;7:799-806. 20. Orhan G, Tasdemir Mete EM, Sargin M, Kudsioglu T, Bayer Erdogan S, et al. Are mechanical assist devices life-saving in acute cardiogenic shock? Turk Gogus Kalp Dama 2016;24:454-61. 19. Haj-Yahia S, Birks EJ, Amrani M, Petrou M, Bahrami T, Dreyfus G, et al. Bridging patients after salvage from bridge to decision directly to transplant by means of prolonged support with the CentriMag short-term centrifugal pump. J Thorac Cardiovasc Surg 2009;138:227-30. 18. Hoefer D, Ruttmann E, Poelzl G, Kilo J, Hoermann C, Margreiter R, et al. Outcome evaluation of the bridge-to-bridge concept in patients with cardiogenic shock. Ann Thorac Surg 2006;82:28-33. 17. Smedira NG, Moazami N, Golding CM, McCarthy PM, Apperson-Hansen C, Blackstone EH, et al. Clinical experience with 202 adults receiving extracorporeal membrane oxygenation for cardiac failure: survival at five years. J Thorac Cardiovasc Surg 2001;122:92-102. 16. Körfer R, El-Banayosy A, Arusoglu L, Minami K, Breymann T, Seifert D, et al. Temporary pulsatile ventricular assist devices and biventricular assist devices. Ann Thorac Surg 1999;68:678-83.